US 12,226,439 B2
Engineered immunostimulatory bacterial strains and uses thereof
Christopher D. Thanos, Tiburon, CA (US); Laura Hix Glickman, Oakland, CA (US); Justin Skoble, Berkeley, CA (US); and Alexandre Charles Michel Iannello, Oakland, CA (US)
Assigned to Actym Therapeutics, Inc., Berkeley, CA (US)
Filed by Actym Therapeutics, Inc., Berkeley, CA (US)
Filed on Sep. 21, 2022, as Appl. No. 17/934,166.
Application 17/934,166 is a division of application No. 17/747,689, filed on May 18, 2022.
Application 17/747,689 is a division of application No. 16/520,155, filed on Jul. 23, 2019, granted, now 11,779,612, issued on Oct. 10, 2023.
Application 17/934,166 is a division of application No. 17/037,455, filed on Sep. 29, 2020.
Application 17/934,166 is a continuation of application No. 16/520,155, filed on Jul. 23, 2019, granted, now 11,779,612, issued on Oct. 10, 2023.
Application 16/520,155 is a continuation of application No. PCT/US2019/041489, filed on Jul. 11, 2019.
Application 17/037,455 is a continuation of application No. PCT/US2019/041489, filed on Jul. 11, 2019.
Application PCT/US2019/041489 is a continuation in part of application No. PCT/US2018/041713, filed on Jul. 11, 2018.
Application PCT/US2019/041489 is a continuation in part of application No. 16/033,187, filed on Jul. 11, 2018, granted, now 11,168,326, issued on Nov. 9, 2021.
Application 17/747,689 is a continuation of application No. 17/037,455, filed on Sep. 29, 2020.
Application 17/037,455 is a continuation of application No. 16/520,155, filed on Jul. 23, 2019, granted, now 11,779,612, issued on Oct. 10, 2023.
Claims priority of provisional application 62/828,990, filed on Apr. 3, 2019.
Claims priority of provisional application 62/789,983, filed on Jan. 8, 2019.
Prior Publication US 2023/0072505 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/74 (2015.01); A61K 39/00 (2006.01); A61K 39/112 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 14/52 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); C12N 1/20 (2006.01); C12N 15/74 (2006.01); C12R 1/42 (2006.01)
CPC A61K 35/74 (2013.01) [A61K 39/0275 (2013.01); A61K 39/4611 (2023.05); A61K 39/4614 (2023.05); A61K 39/4622 (2023.05); A61K 39/4644 (2023.05); A61K 39/464832 (2023.05); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C07K 16/248 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 1/205 (2021.05); C12N 15/74 (2013.01); A61K 45/06 (2013.01); A61K 2239/50 (2023.05); C12R 2001/42 (2021.05)] 41 Claims
 
1. A method of treatment of cancer, comprising administering an immunostimulatory bacterium, wherein:
the immunostimulatory bacterium comprises a plasmid that encodes an anti-cancer therapeutic product;
the genome of the immunostimulatory bacterium is modified so that the bacterium is taken up by phagocytic cells and does not infect epithelial cells; and
the bacterium without the modifications does infect epithelial cells.